By modulating APP processing, BACE1 expression, and autophagic clearance, S6K1 inhibition emerges as a promising therapeutic strategy for reducing Aβ accumulation and rescuing cognitive decline in AD. The gene discussed is APP; the disease is Alzheimer disease.